Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer.

Abstract:

:Non-small cell lung cancer (NSCLC) represents almost three quarters of all cases of lung cancer. Most NSCLC patients present with either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that make them unsuitable for curative resection. Among NSCLC patients in the United States, overall 5-year survival rates range from 10% to 15%. Systemic chemotherapy has had minimal impact on prolonging survival or improving quality of life. Combination chemotherapy regimens containing cisplatin usually produce the best overall response rates. Combination chemotherapy in one study also has been shown to be more efficacious and less expensive than best supportive care. Newer cytotoxic agents, including vinorelbine, gemcitabine, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), docetaxel, and the camptothecins, have shown promise in the treatment of NSCLC. In combination with other effective agents (eg, cisplatin), response rates approaching 50% have been observed. A greater understanding of the biologic properties of lung cancer may help facilitate early detection and chemoprevention in patients at risk.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Carney DN

subject

Has Abstract

pub_date

1995-08-01 00:00:00

pages

58-62

issue

4 Suppl 9

eissn

0093-7754

issn

1532-8708

journal_volume

22

pub_type

杂志文章,评审
  • Pathologic prognostic factors in esophageal carcinoma.

    abstract::Thus, many interesting and promising techniques are now available for the study of potential prognostic factors in esophageal carcinoma, and the results may supplement the information that is obtained by routine histopathologic analysis. It may become possible to define subgroups of patients with lower risk tumors, fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Klimstra DS

    更新日期:1994-08-01 00:00:00

  • Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

    abstract::Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor family, which produces factors that are considered to be important mediators of cell growth. Overexpression of HER2, which occurs in approximately 25% to 30% of human breast cancers, has fostered considerable interest i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ewer MS,Gibbs HR,Swafford J,Benjamin RS

    更新日期:1999-08-01 00:00:00

  • Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.

    abstract::Diffuse large B-cell lymphoma (DLCL) is the most frequently diagnosed subtype of non-Hodgkin's lymphoma (NHL), and more than 50% of cases present in patients over 60 years of age. Although cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) is currently regarded as the gold standard treatment for DLCL, less tha...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.32749

    authors: Coiffier B

    更新日期:2002-04-01 00:00:00

  • High-dose megestrol acetate in the treatment of advanced breast cancer.

    abstract::A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue. In 1985, we began a phase I-II study of high-dose megestrol acetate in dosages of 480 mg/d to 1,600 mg/d in heavily pretreated postme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Tchekmedyian NS,Tait N,Abrams J,Aisner J

    更新日期:1988-04-01 00:00:00

  • The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

    abstract::The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.07.005

    authors: Wickerham DL,O'Connell MJ,Costantino JP,Cronin WM,Paik S,Geyer CE Jr,Ganz PA,Petrelli N,Mamounas EP,Julian TB,Wolmark N

    更新日期:2008-10-01 00:00:00

  • Third-line salvage chemotherapy in Hodgkin's disease.

    abstract::CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonadonna G,Viviani S,Valagussa P,Bonfante V,Santoro A

    更新日期:1985-03-01 00:00:00

  • Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?

    abstract::The development of targeted agents has brought new opportunities and extraordinary therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor receptor (HER1/EGFR) tyrosine kinase have been developed and are advanced in their clinical development. Preclinical and clinical data show th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Hortobagyi GN,Sauter G

    更新日期:2003-06-01 00:00:00

  • Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.

    abstract::Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria for an effective combination include use of drugs with different mechanisms of action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; B...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Holmes FA

    更新日期:1996-10-01 00:00:00

  • Implications of the new biology for therapy in breast cancer.

    abstract::It is a truism that a better understanding of the biology of breast cancer should lead to improvements in diagnosis and therapy. Despite this, our significantly improved grasp of breast cancer biology has had little direct therapeutic impact to date. The technologies used to treat breast cancer (surgery, radiation the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sledge GW Jr

    更新日期:1996-02-01 00:00:00

  • Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.

    abstract::To improve the resectability and long-term local control of locally advanced rectal cancer, we have initiated a radiation dose-escalation trial. It is hoped that the radioprotector amifostine will sufficiently reduce rectal morbidity (without also reducing tumor response) to permit increasing radiation doses. Only 6 p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2002.37360

    authors: Myerson R,Zobeiri I,Birnbaum E,Dietz D,Fleshman J,Kodner I,Picus J,Ratkin G

    更新日期:2002-12-01 00:00:00

  • Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

    abstract::Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.05.006

    authors: Obeid J,Hu Y,Slingluff CL Jr

    更新日期:2015-08-01 00:00:00

  • Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.

    abstract::Combination antimicrotubule therapy with estramustine phosphate (EMP) and vinblastine has reproducible activity in metastatic hormone-refractory prostate cancer (HRPC) with an objective response rate of 31%. Although paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 24-hour infusion was inactive in HR...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hudes GR,Nathan FE,Khater C,Greenberg R,Gomella L,Stern C,McAleer C

    更新日期:1995-10-01 00:00:00

  • Defining the clinical diagnosis of inflammatory breast cancer.

    abstract::Inflammatory breast cancer (IBC) is an extremely aggressive disease that progresses rapidly and carries a very grim prognosis. It is characterized by erythema, rapid enlargement of the breast, skin ridging, and a characteristic peau d'orange appearance of the skin secondary to dermal lymphatic tumor involvement. Altho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.11.010

    authors: Singletary SE,Cristofanilli M

    更新日期:2008-02-01 00:00:00

  • A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.

    abstract::Since its approval in 2011 for patients with recurrent glioblastoma (GBM), physicians have responded positively to the non-invasive nature of the NovoTTF-100A System device (NovoCure Ltd, Haifa, Israel), citing significantly less toxicity and a better quality of life profile compared to available conventional therapie...

    journal_title:Seminars in oncology

    pub_type:

    doi:10.1053/j.seminoncol.2013.10.002

    authors: Butowski N,Wong ET,Mehta MP,Wilson LK

    更新日期:2013-12-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • Topotecan in advanced colorectal cancer.

    abstract::Colorectal cancer is the third most common cause of cancer-related death in both men and women. Surgery is the primary form of treatment, with greater than 90% of patients surviving 5 years or more. The remaining patients have metastatic disease, for which treatment options are limited. The fluoropyrimidine, 5-fluorou...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Creemers GJ

    更新日期:1997-12-01 00:00:00

  • Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.

    abstract::Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid, and ifosfamide have each shown activity as a single agent and in various combination-chemotherapy regimens against non-small cell lung cancer. Vinorelbine usually has been...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Masters GA,Hoffman PC,Drinkard LC,Watson S,Samuels BL,Golomb HM,Vokes EE

    更新日期:1996-04-01 00:00:00

  • Single-agent oral etoposide for elderly small cell lung cancer patients.

    abstract::Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

    更新日期:1990-02-01 00:00:00

  • Screening diagnosis and staging of esophageal cancer.

    abstract::In geographic areas where there is a high risk of esophageal cancer, analysis of cells obtained from the esophagus has been used effectively to detect early lesions. This has been demonstrated on a large scale in studies from China. Using abrasive balloon cytology techniques, 75% of the cancers detected were early les...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Lightdale CJ,Winawer SJ

    更新日期:1984-06-01 00:00:00

  • Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.

    abstract::Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant c...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

    更新日期:1988-02-01 00:00:00

  • From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

    abstract::Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise revi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.08.005

    authors: Caruana I,Diaconu I,Dotti G

    更新日期:2014-10-01 00:00:00

  • Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.

    abstract::Oxaliplatin, which was recently approved by the US Food and Drug Administration for the treatment of advanced colorectal cancer, is often administered to patients with altered liver function caused by hepatic metastases. Because of the absence of data on the clearance of oxaliplatin in patients with liver dysfunction,...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0093-7754(03)00400-7

    authors: Doroshow JH,Synold TW,Gandara D,Mani S,Remick SC,Mulkerin D,Hamilton A,Sharma S,Ramanathan RK,Lenz HJ,Graham M,Longmate J,Takimoto CH,Ivy P

    更新日期:2003-08-01 00:00:00

  • The human interferon-alpha species and hybrid proteins.

    abstract::Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Pestka S

    更新日期:1997-06-01 00:00:00

  • Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.

    abstract::Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Diehl LF,Ketchum LH

    更新日期:1998-02-01 00:00:00

  • Pox viral vaccine approaches.

    abstract::Recent advances in understanding tumor-specific immunity have introduced new excitement in the clinical development of vaccines for the treatment of cancer. A better understanding of basic immunologic principles has led to a variety of techniques for enhancing tumor-specific immunity through vaccination. Approaches to...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.09.006

    authors: Arlen PM,Kaufman HL,DiPaola RS

    更新日期:2005-12-01 00:00:00

  • Clinicopathologic factors influencing the long-term prognosis following hepatic resection for large hepatocellular carcinoma more than 10 cm in diameter.

    abstract::We resected 158 cases of hepatocellular carcinoma (HCC), including 20 (12.6%) cases of large HCC. These 20 cases were divided into group 1 (curative resection, n = 9) and group 2 (noncurative resection, n = 11). The clinicopathologic features and long-term survival of the cases were evaluated. In groups 1 and 2, porta...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Noguchi T,Kawarada Y,Kitagawa M,Ito F,Sakurai H,Machishi H,Yamagiwa K,Yokoi H,Mizumoto R

    更新日期:1997-04-01 00:00:00

  • Sequencing therapy in metastatic renal cell cancer.

    abstract::The sequencing of targeted therapy is well established in metastatic renal cancer. Switching between different vascular endothelial growth factor (VEGF)-targeted therapies or VEGF-targeted therapies and mammalian target of rapamycin (mTOR) inhibitors are both of proven benefit. The optimal sequence remains unclear. Un...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.05.002

    authors: Escudier B,Gore M

    更新日期:2013-08-01 00:00:00

  • Mechanisms of drug resistance in breast cancer.

    abstract::Drug resistance is one of the most important problems in the treatment of cancer. Patients become resistant not only to the drugs used initially, but also those to which they have not yet been exposed. A number of factors influence the therapeutic outcome of patients with breast cancer, foremost of which is the tumor ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalton WS

    更新日期:1990-08-01 00:00:00

  • The role of interferon in the therapy of epidemic Kaposi's sarcoma.

    abstract::Kaposi's sarcoma (KS) is the major neoplastic complication of the acquired immune deficiency syndrome (AIDS). Although most patients succumb to infectious complications of AIDS rather than as a direct consequence of the tumor, KS may, in some cases, pursue an aggressive clinical course resulting in considerable morbid...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Krown SE

    更新日期:1987-06-01 00:00:00

  • Critical evaluation of prognostic factors.

    abstract::The ability to predict the biological behavior of breast tumors can allow selection of the optimum treatment and follow-up strategies. Conventionally, tumor size, lymph node metastases, and histopathologic features have been used to determine the risk of systemic relapse. The discovery of a number of specific genetic ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dhingra K,Hortobagyi GN

    更新日期:1996-08-01 00:00:00